A universal CAR-T cell and its preparation method and application
Through the overexpression of human TCR inhibitors and the binding of chimeric antigen receptors, the use of lentiviral vectors to directly transfect T cells without gene editing, solving the electric shock damage and off-target risks caused by gene editing in CAR-T cell therapy, simplifying the The preparation process reduces costs and cycles, and improves efficacy and safety.
Patent Information
- Application Number
- CN202211252414.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-13
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-10-13
AI Technical Summary
Existing CAR-T cell therapies require gene editing, resulting in electric shock damage and off-target risks, and have a long preparation cycle and high cost. It is especially difficult for newborns and elderly people to obtain sufficient qualified autologous T cells, and allogeneic CAR-T Cells face the problems of immune rejection and graft-versus-host disease.
Overexpression of human TCR inhibitors is used to interfere with the formation of the CD3-TCR complex, bind to chimeric antigen receptors, and directly transfect T cells through lentiviral vectors without gene editing, simplifying the preparation process and avoiding gene editing steps and electric shock damage.
Gene-edit-free universal CAR-T cell preparation is achieved, reducing production costs and treatment cycles, reducing allopathic reactivity, and improving efficacy and safety.
Smart Images

Figure CN115747166B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a universal CAR-T cell that does not require gene editing, and a preparation method and application thereof. Background Art
[0002] Tumor treatment is one of the biggest problems that plagues mankind, and conventional treatment methods all have their limitations. With the advancement of science and technology, and the development of tumor immunology theory and technology, tumor immunotherapy is gradually becoming the development direction of tumor treatment and is known as the fourth tumor treatment technology. As a new favorite in the field of tumor immunotherapy, immune cell therapy technology has developed rapidly in recent years. Studies have found that T lymphocytes are the natural enemies of tumor cells, play a major role in tumor immune response, and have a strong killing effect on tumor cells.
[0003] CAR-T cell (chimeric antigen receptor T cell) technology is an immune cell therapy that uses the patient's own immune cells to eliminate cancer cells. Chimeric Antigen Receptor (CAR) is an artificial receptor that simulates TCR function and is composed of an antigen recognition domain, a hinge region, a transmembrane region, and an intracellular signaling domain. The antigen recognition domain is usually a single-chain antibody that specifically binds to the target. Chimeric antigen receptor T cells (CAR-T cells) are T cells expressing CAR obtained by genetically modifying and transforming exogenous artificially designed CAR genes into T cells. Since tumor immunotherapy can cure tumors without the therapeutic toxicity of traditional radiotherapy and chemotherapy, immune cell therapy has broad prospects in the treatment of tumors.
[0004] CAR-T immunotherapy has achieved unprecedented success in treating blood tumors. Kymriah and Yescarta, two CAR-T products developed by Novartis and Gilead (acquired Kite Pharma), were approved by the FDA in 2017, bringing hope to thousands of cancer patients around the world. So far, five CAR-T drugs for blood tumors have been approved by the FDA.
[0005] However, the current standard CAR-T therapy requires obtaining sufficient autologous T cells from the patient for conversion to CAR-T, which is time-consuming, labor-intensive, and expensive. For newborns and the elderly, as well as some patients with poor autoimmune function, it is even difficult to obtain sufficient and qualified T cells for subsequent conversion to CAR-T. In order to make CAR-T therapy easier to implement, it is urgent to develop a human universal CAR-T, that is, the T cells used to convert CAR-T come from healthy individuals, but the produced CAR-T can be used for different patients. The number of peripheral blood T cells of healthy donors is large and the viability is high, which is relatively easy to prepare CAR-T and cell amplification; if it can be used to replace the autologous CAR-T cells of tumor patients for treatment, it will greatly reduce the cycle of CAR-T cell preparation and the cost of treatment.
[0006] The main obstacle to the use of allogeneic CAR-T cells in tumor treatment is the problem of immune rejection, a process called host antigen graft rejection, which greatly limits the anti-tumor function of allogeneic CAR-T cells. Another manifestation is that allogeneic CAR-T cells may recognize host tissues as foreign, leading to graft-versus-host disease (GvHD), which may cause severe tissue damage and death. At present, allogeneic CAR-T cell technology mainly relies on gene editing platforms to generate site-specific double-strand breaks at specific locations in the genome (such as TCR, HLA), and then repair them through non-homologous end joining (NHEJ) or homology-directed recombination repair (HDR), thereby achieving targeted knockout of genes (TCR and HLA molecules, etc.) from T cells in healthy human blood to reduce or eliminate the graft-versus-host disease (GvHD) caused by them. There are currently three mature gene editing technologies: zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR). However, all of these technologies require T cell gene editing, and because the gene editing enzyme fragments required for the above gene editing technologies are relatively large, these gene editing technologies can only be used through electroporation, which can cause T cell damage, and gene editing tools have potential off-target risks, as well as other inevitable problems such as gene editing efficiency.
[0007] Therefore, there is an urgent need in this field to develop a universal CAR-T cell that does not require gene editing to solve the current problems. Summary of the invention
[0008] The first objective of the present invention is to obtain universal CAR-T cells that do not require gene editing.
[0009] The second objective of the present invention is to obtain a method for preparing universal CAR-T cells that do not require gene editing.
[0010] The third object of the present invention is to provide a pharmaceutical composition containing universal CAR-T cells that do not require gene editing.
[0011] The fourth objective of the present invention is to obtain a pharmaceutical composition containing universal CAR-T cells that do not require gene editing.
[0012] The first aspect of the present invention provides a universal CAR-T cell, which expresses a chimeric antigen receptor for a target cell surface antigen and a human TCR inhibitory factor, wherein the human TCR inhibitory factor is derived from the human CD3ζ gene, and the nucleotide sequence of the human TCR inhibitory factor is shown in SEQ ID NO.7.
[0013] In a preferred embodiment of the present invention, the chimeric antigen receptor and the TCR inhibitor are connected by a cleavage protein.
[0014] In a preferred embodiment of the present invention, the shear protein is any one of T2A or P2A, and the nucleotide sequences are shown in SEQ ID NO. 8 and SEQ ID NO. 9 respectively.
[0015] Furthermore, the shear protein is preferably P2A, and the nucleotide sequence is shown in SEQ ID NO.9.
[0016] In a preferred embodiment of the present invention, the universal CAR-T cells are universal CAR-T cells that do not require gene editing.
[0017] In a preferred embodiment of the present invention, the universal CAR-T cells simultaneously express a chimeric antigen receptor for a target cell surface antigen and the human TCR inhibitor.
[0018] Preferably, the simultaneous expression means that the chimeric antigen receptor and TCR inhibitor are transcribed by the same promoter.
[0019] More preferably, the same promoter may be one of CMV and EF1a promoters, most preferably EF1a promoter.
[0020] In a preferred embodiment of the present invention, the TCR inhibitor interferes with the formation of the CD3-TCR complex in the universal CAR-T cells.
[0021] In a preferred embodiment of the present invention, the chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain, a co-stimulatory domain and a signal transduction domain.
[0022] Preferably, the signal peptide is CD8 leader, which can express a leader peptide that guides newly synthesized proteins to transfer across the membrane. The nucleotide sequence of the CD8 leader is shown in SEQ ID NO.1.
[0023] Preferably, the transmembrane domain is CD8α, connecting the extracellular antigen binding domain and the intracellular signaling domain, and the nucleotide sequence is as shown in SEQ ID NO.3.
[0024] Preferably, the co-stimulatory domain is CD28 or 4-1BB, the CD28 nucleotide sequence is shown in SEQ ID NO.4, and the 4-1BB nucleotide sequence is shown in SEQ ID NO.5.
[0025] Preferably, the signal transduction domain is CD3ζ, and the nucleotide sequence is shown in SEQ ID NO.6.
[0026] In a preferred embodiment of the present invention, the tumor surface antigen targeted by the chimeric antigen receptor on the surface of the CAR-T cell is at least one of CD19, CD20, BCMA, CD22, CD30, CD123, CD5, CD7, CD33, CEA, EGFR, BRAF, HER-2, Mesothelin, MUC1, PSCA, GPC3, TERT, B7H3, PTEN, PD-1, PD-L1, NKG2D ligand, CD44v6, FR, CD138, PSMA, NY-ESO, EGFR, CEA, HER2, Mesothelin, GD2, CD171, GPC3 or VEGF.
[0027] In a preferred embodiment of the present invention, the vector used for preparing the universal CAR-T cells is DNA, RNA, plasmid, lentiviral vector, adenoviral vector, retroviral vector, transposon, other gene transfer system, or a combination thereof.
[0028] More preferably, the vector is a lentiviral vector.
[0029] Most preferably, the promoter used to initiate translation of the chimeric antigen receptor and TCR inhibitor in the lentiviral vector is any one of CMV or EF1a.
[0030] Another aspect of the present invention provides a vector, characterized in that it comprises a nucleic acid for encoding the chimeric antigen receptor and human TCR inhibitor as described above.
[0031] The vector used is DNA, RNA, plasmid, lentiviral vector, adenoviral vector, retroviral vector, transposon, other gene transfer system, or a combination thereof;
[0032] More preferably, the vector is a lentiviral vector.
[0033] Most preferably, the promoter used to initiate translation of the chimeric antigen receptor and TCR inhibitor in the lentiviral vector is any one of CMV or EF1a.
[0034] Another aspect of the present invention provides a virus comprising the vector of the present invention.
[0035] Another aspect of the present invention provides a method for preparing the universal CAR-T cells of the present invention, comprising the following steps:
[0036] Providing a T cell to be modified; and
[0037] The T cells are modified so that the T cells express the CAR, and the T cells express a chimeric antigen receptor and a human TCR inhibitor for the target cell surface antigen, wherein the nucleotide sequence of the human TCR inhibitor is as shown in SEQ ID NO.7.
[0038] In a preferred embodiment, a method for preparing universal CAR-T cells comprises the following steps:
[0039] 1) Vector construction;
[0040] 2) using the carrier for packaging preparation;
[0041] 3) T cell activation;
[0042] 4) transfecting activated T cells with the vector;
[0043] 5) Sorting out CAR-T cells;
[0044] 6) Anti-tumor function detection of CAR-T cells after sorting;
[0045] 7) GVHD test of sorted CAR-T cells.
[0046] More specifically, the present invention provides a universal CAR-T cell free of gene editing and a preparation method and application thereof, including first preparing chimeric antigen receptor and TCR inhibitor genes, inserting the synthesized insertion sequence into the framework of the pLenti-MCS-EF1-GFP Lentiviral Expression Vector plasmid vector, the expression vector includes: EF1a promoter; the position for inserting foreign genes; WPRE element; SV40 polyA sequence; regulatory elements such as promoters and enhancers; lentiviral packaging elements and other key elements. The lentiviral expression vector can be used as the most effective vector for expressing the target gene in almost all mammalian cells, including non-dividing cells and dividing cells. It can accommodate large foreign gene fragments, has high transfection efficiency, and can also achieve satisfactory transfection effects on T cells.
[0047] Another aspect of the present invention is a pharmaceutical composition, comprising:
[0048] (a) the universal CAR-T cell of the present invention; and
[0049] (b) a pharmaceutically acceptable carrier, diluent or excipient.
[0050] The use of the universal CAR-T cells of the present invention is, among other things, for preparing a pharmaceutical composition or preparation for preventing and / or treating cancer.
[0051] In a preferred example, the tumor is selected from the following group: blood tumor, solid tumor, or a combination thereof.
[0052] Preferably, the tumor includes any one of liver cancer, head and neck cancer, melanoma, bladder cancer, various leukemias, multiple myeloma and malignant lymphoma, glioblastoma, cervical cancer, lung cancer, chondrosarcoma, thyroid cancer, kidney cancer, mesothelioma, osteosarcoma, rectal cancer, anal cancer, bile duct cancer, uterine cancer, ovarian cancer, gastric cancer, prostate cancer, meningioma, pancreatic cancer, multiple squamous cell neoplasia, esophageal cancer, colorectal cancer, breast cancer or medulloblastoma, or a combination of at least two of them.
[0053] The present invention can bring at least one of the following beneficial effects:
[0054] The present invention has the following beneficial effects: after using the virus to infect T cells, pure universal CAR-T cells can be obtained by directly performing cell sorting in the later stage, eliminating the gene editing step; the process of preparing universal CAR-T cells in the present invention avoids the off-target effects caused by gene editing and the damage to cells caused by electric shock, simplifies the production process, saves production costs, and has great application value in the field of tumor immune cell therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] The preferred implementation scheme will be described below in a clear and understandable manner with reference to the accompanying drawings to further illustrate the above-mentioned characteristics, technical features, advantages and their implementation methods.
[0056] Figure 1 This is a schematic diagram of the structure of the universal CAR free of gene editing of the present invention;
[0057] Figure 2 This is an agarose gel electrophoresis diagram of the double enzyme digestion product of the universal CAR-T vector free of gene editing of the present invention;
[0058] Figure 3a~Figure 3e It is a flow cytometry detection diagram of common CAR-T cells and universal CAR-T cells without gene editing of the present invention, wherein, Figure 3a This is the detection chart of uninfected T cells. Figure 3b This is the detection chart of common anti-MSLN CAR T cells after infection. Figure 3c This is the detection picture of ordinary anti-MSLN CAR T cells after sorting. Figure 3d This is the detection diagram of universal anti-MSLN CAR T cells after infection. Figure 3e This is the detection diagram of universal anti-MSLN CAR T cells after sorting;
[0059] Figure 4 This is a qPCR detection diagram of TI expression in common CAR-T cells and the universal CAR-T cells without gene editing of the present invention;
[0060] Figure 5a This is a flow cytometric detection diagram of MSLN expression in tumor target cells without staining with MSLN flow cytometric antibody;
[0061] Figure 5b This is a flow cytometric detection diagram of MSLN expression in tumor target cells stained with MSLN flow cytometric antibody;
[0062] Figure 6a It is a killing efficiency curve diagram of common CAR-T cells and universal CAR-T cells without gene editing detected by RTCA of the present invention on ES2 cells;
[0063] Figure 6b It is a killing efficiency curve diagram of common CAR-T cells and universal CAR-T cells without gene editing detected by RTCA of the present invention on SKOV3 cells;
[0064] Figure 7 It is an ELISA detection bar graph of IFNγ factor after ES2 cells and SKOV3 cells were killed by common CAR-T cells and the universal CAR-T cells without gene editing of the present invention for 24 hours.
[0065] Figure 8 This is a diagram showing the inhibitory effects of common CAR-T cells and the universal CAR-T cells of the present invention that do not require gene editing on allogeneic reactivity (GVHD effect) in a mouse model. DETAILED DESCRIPTION
[0066] In the present invention, the inventors have conducted extensive and in-depth experiments and proved through experiments that the overexpressed TCR inhibitor of human origin can greatly interfere with the formation of normal CD3-CR complexes, thereby inhibiting or even eliminating the production of GVHD; at the same time, a universal CAR-T is constructed based on the overexpressed TCR inhibitor of human origin, without the need for gene editing steps. This avoids the off-target effects caused by gene editing and the cell damage caused by gene editing electroporation experiments, greatly simplifying the universal CAR-T production process.
[0067] Therefore, the technical problem solved by the present invention is that the gene editing technology usually required by the prior art can only be used through electric shock transduction, which can cause T cell damage, and the gene editing tool contains potential off-target risks, as well as other inevitable problems such as gene editing efficiency.
[0068] The technical concept adopted by the present invention includes: the use of human overexpressed TCR inhibitors can greatly interfere with the formation of normal CD3-CR complexes, thereby inhibiting or even eliminating the production of GVHD; at the same time, a universal CAR-T is constructed based on the human overexpressed TCR inhibitor, without the need for gene editing steps. And it can be used for universal CAR-T cells. More preferably, the universal CAR-T cells simultaneously express chimeric antigen receptors for target cell surface antigens and the human TCR inhibitor.
[0069] Compared with conventional processes, the present invention can achieve a comparable effect of avoiding the occurrence of GVHD even without using gene editing technology, thus achieving an unexpected effect.
[0070] Unless otherwise clearly specified and limited, the "or" mentioned in the present invention includes the relationship of "and". The "and" is equivalent to the Boolean logic operator "AND", the "or" is equivalent to the Boolean logic operator "OR", and "AND" is a subset of "OR".
[0071] In the present invention, the terms "comprising", "including" or "comprising" indicate that various components can be applied together in the mixture or composition of the present invention. Therefore, the terms "consisting mainly of" and "consisting of" are included in the terms "comprising", "including" or "comprising".
[0072] The various aspects of the present invention are described in detail below:
[0073] the term
[0074] As used herein, the term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.
[0075] As used herein, the terms "administering", "administering" and "administering" are used interchangeably and refer to the physical introduction of the product of the present invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.
[0076] CAR
[0077] The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain, a co-stimulatory domain and a signal transduction domain: preferably, the signal peptide is CD8 leader, which can express a leader peptide that guides the newly synthesized protein to transfer across the membrane, and the nucleotide sequence of the CD8 leader is shown in SEQ ID NO.1,
[0078] Preferably, the transmembrane domain is CD8α, connecting the extracellular antigen binding domain and the intracellular signaling domain, and the nucleotide sequence is as shown in SEQ ID NO. 3,
[0079] Preferably, the co-stimulatory domain is CD28 or 4-1BB, the CD28 nucleotide sequence is shown in SEQ ID NO.4, and the 4-1BB nucleotide sequence is shown in SEQ ID NO.5.
[0080] Preferably, the signal transduction domain is CD3ζ, and the nucleotide sequence is shown in SEQ ID NO.6.
[0081] The TCR inhibitor is derived from the human CD3ζ gene, and the nucleotide sequence is shown in SEQ ID NO. 7. The chimeric antigen receptor and the TCR inhibitor are connected by a cleavage protein, preferably, the cleavage protein is any one of T2A or P2A, and the nucleotide sequence is shown in SEQ ID NO. 8 and SEQ ID NO. 9.
[0082] The tumor surface antigen targeted by the chimeric antigen receptor on the surface of the CAR-T cell is at least one of CD19, CD20, BCMA, CD22, CD30, CD123, CD5, CD7, CD33, CEA, EGFR, BRAF, HER-2, Mesothelin (MSLN), MUC1, PSCA, GPC3, TERT, PTEN, PD-1, PD-L1, NKG2D ligand, CD44v6, FR, CD138, PSMA, NY-ESO, EGFR, CEA, HER2, Mesothelin, GD2, CD171, GPC3 or VEGF.
[0083] As used herein, the terms "linker", "hinge region" are used interchangeably and generally refer to any oligopeptide or polypeptide that functions to connect a transmembrane domain to an extracellular domain or cytoplasmic domain of a polypeptide chain. The linker may include 0-300 amino acids, preferably 2 to 100 amino acids and most preferably 3 to 50 amino acids.
[0084] As used herein, the basic structure of the chimeric antigen receptor of the present invention includes: a tumor-associated antigen binding region, an extracellular hinge region, a transmembrane region and an intracellular signal region. The selection of tumor-associated antigens directly affects their therapeutic effects on tumors.
[0085] CAR-T
[0086] A universal CAR-T cell that does not require gene editing, in which a chimeric antigen receptor and a TCR inhibitor targeting a target cell surface antigen are expressed.
[0087] The human TCR inhibitor is derived from the human CD3ζ gene, and the nucleotide sequence of the human TCR inhibitor is shown in SEQ ID NO.7.
[0088] The present invention may also include fragments, derivatives and analogs of the human TCR inhibitor.
[0089] As used herein, the terms "fragment", "derivative" and "analog" refer to a nucleotide that substantially retains the same biological function or activity of the human TCR inhibitor of the present invention.
[0090] The TCR inhibitor interferes with the formation of the CD3-TCR complex in the universal CAR-T cells.
[0091] The universal CAR-T cell without gene editing and its preparation method and application include the following steps: 1) viral vector construction; 2) using the vector for viral packaging preparation; 3) T cell sorting and activation; 4) viral transfection of activated T cells; 5) sorting CAR-T cells; 6) anti-tumor function detection of sorted CAR-T cells; 7) GVHD experimental detection of sorted CAR-T cells.
[0092] The universal CAR-T cell that does not require gene editing is a drug for tumor treatment; preferably, the tumor includes any one of liver cancer, head and neck cancer, melanoma, bladder cancer, various leukemias, multiple myeloma and malignant lymphoma, glioblastoma, cervical cancer, lung cancer, chondrosarcoma, thyroid cancer, kidney cancer, mesothelioma, osteosarcoma, rectal cancer, anal cancer, bile duct cancer, uterine cancer, ovarian cancer, gastric cancer, prostate cancer, meningioma, pancreatic cancer, multiple squamous cell tumors, esophageal cancer, colorectal cancer, breast cancer or medulloblastoma, or a combination of at least two of them.
[0093] In a preferred embodiment of the present invention, the vector is a lentiviral vector. The vector used for preparing the universal CAR-T cells is a lentiviral vector.
[0094] Preferably, the promoter used to initiate the translation of the chimeric antigen receptor and TCR inhibitor in the lentiviral vector is any one of CMV and EF1a.
[0095] Pharmaceutical composition
[0096] The present invention provides a pharmaceutical composition comprising the universal CAR-T cells described in the first aspect of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient. In one embodiment, the pharmaceutical composition is a liquid preparation. Preferably, the preparation is an injection. Preferably, the concentration of the CAR-T cells in the preparation is 1×10 4 -1×10 8 cells / ml, preferably 1×10 5 -1×10 6 cells / ml.
[0097] In one embodiment, the formulation may include a buffer such as neutral buffered saline, sulfate buffered saline, etc.; a carbohydrate such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid such as glycine; an antioxidant; a chelating agent such as EDTA or glutathione; an adjuvant (e.g., aluminum hydroxide); and a preservative. The formulation of the present invention is preferably formulated for intravenous administration.
[0098] The present invention also provides the use of the universal CAR-T cells of the first aspect of the present invention and the pharmaceutical composition of the third aspect of the present invention for preparing a pharmaceutical composition or preparation for preventing and / or treating cancer, and for treating / or preventing cancer.
[0099] The cancer includes tumors at various stages of progression, including clinically stage I to stage IV tumors. Cancer may include non-solid tumors (such as hematological tumors, such as leukemia and lymphoma) or solid tumors. The types of cancer treated with the CAR of the present invention include, but are not limited to, cancer, blastoma and sarcoma, and certain leukemia or lymphoma, benign and malignant tumors, and malignant tumors, such as sarcoma, cancer and melanoma. Also included are adult tumors / cancers and childhood tumors / cancers.
[0100] Hematological cancers are cancers of the blood or bone marrow. Examples of hematological (or hematogenous) cancers include leukemias, including acute leukemias (such as acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, and myeloblastic, promyelocytic, myelo-monocytic, monocytic, and erythroleukemias), chronic leukemias (such as chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphomas, Hodgkin's disease, non-Hodgkin's lymphomas (indolent and high-grade forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia, and myelodysplasia.
[0101] Solid tumors are abnormal masses of tissue that usually do not contain cysts or fluid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named after the cell types that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumors such as sarcomas and carcinomas include fibrosarcomas, myxosarcoma, liposarcoma mesothelioma, lymphoid malignancies, pancreatic cancer, ovarian cancer.
[0102] The universal CAR-T cells of the present invention can also be used as a vaccine type for ex vivo immunization and / or in vivo therapy of mammals. Preferably, the mammal is a human.
[0103] For ex vivo immune cell preparation, at least one of the following occurs in vitro prior to administering the cells into a mammal: i) expanding the cells, ii) introducing a nucleic acid encoding a CAR into the cells, and / or iii) cryopreserving the cells.
[0104] Ex vivo cell processing procedures are well known in the art and are discussed more fully below. Briefly, cells are isolated from mammals (preferably humans) and genetically modified (i.e., in vitro transduction or transfection) with vectors expressing the CAR disclosed herein. CAR-modified cells can be administered to mammalian recipients to provide therapeutic benefits. The mammalian recipient can be a human, and the CAR-modified cells can be autologous, allogeneic, or syngeneic relative to the recipient.
[0105] In addition to the use of cell-based vaccines with respect to immune cells ex vivo, the present invention also provides compositions and methods for use in vivo to enhance the immune response to a targeted antigen in a patient.
[0106] The present invention provides a method for treating tumors, comprising administering an effective amount of the universal CAR-T cells of the present invention to a subject in need thereof.
[0107] The universal CAR-T cells of the present invention can be administered alone or as a pharmaceutical composition in combination with a diluent and / or with other components such as IL-2, IL-15, IL-17 or other cytokines or cell populations.
[0108] The pharmaceutical composition of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the characteristics of the patient's condition, the type and severity of the disease - although the appropriate dosage can be determined by clinical trials.
[0109] When an "immunologically effective amount", "anti-tumor effective amount", "tumor-suppressive effective amount" or "therapeutic amount" is indicated, the exact amount of the composition of the present invention to be administered can be determined by a physician, who takes into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. It can be generally stated that the pharmaceutical composition comprising the T cells described herein can be administered in an amount of 10 4 Up to 10 9 The dosage is preferably 10 cells / kg body weight. 5 Up to 10 7 The T cell composition can also be administered multiple times at these doses. The cells can be administered using well-known infusion techniques in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988). The optimal dose and treatment regimen for a specific patient can be determined by monitoring the patient's disease signs, and the treatment regimen is determined by a medical technician.
[0110] The administration of the subject composition can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The composition described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranodally, intraspinal, intramuscularly, intravenously (iv.) or intraperitoneally or intrapleurally. In another embodiment, the T cell composition of the present invention is preferably administered by i.v. intravenous injection. The composition of T cells can be directly injected into tumors, lymph nodes or infection sites. (CART cell products are mainly intravenous infusions, and can be directly injected into tumors, lymph nodes or infection sites)
[0111] In certain embodiments of the invention, cells are activated and expanded using the methods described herein or other methods known in the art for expanding T cells to therapeutic levels, and are administered to a patient in combination with (e.g., before, simultaneously with, or after) any number of relevant treatment modalities, including, but not limited to, treatment with agents such as antiviral therapy, cidofovir, interleukin-2, IFN-γ, cytarabine (also known as ARA-C) and other cytotoxic chemotherapy drugs, checkpoint inhibitors such as PD-1 antibodies, anti-CTLA-4 antibodies, and drugs that inhibit cytokine storms such as tocilizumab, an anti-IL-6 receptor, and other treatments.
[0112] In further embodiments, the T cells of the invention can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate, and antibodies or other immunotherapeutic agents. In further embodiments, the cell compositions of the invention are administered to a patient in combination with (e.g., before, simultaneously with, or after) bone marrow transplantation, chemotherapy such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide.
[0113] For example, in one embodiment, a subject may undergo standard treatment with high-dose chemotherapy followed by a peripheral blood stem cell transplant.
[0114] In some embodiments, the subject receives an infusion of the expanded immune cells of the invention following transplantation. In an additional embodiment, the expanded cells are administered prior to or after surgery.
[0115] The dosage of the above treatments administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The dosage ratio for human administration can be implemented according to practices accepted in the art. Typically, 1×10 6 to 1×10 10 The universal CAR-T cells of the present invention are administered to patients, for example, by intravenous infusion.
[0116] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not indicated in the following examples are usually measured according to national standards. If there is no corresponding national standard, then proceed according to general international standards, normal conditions, or according to the conditions recommended by the manufacturer. Unless otherwise stated, all parts are by weight, all percentages are by weight, and the polymer molecular weight is the number average molecular weight.
[0117] Unless otherwise defined or indicated, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the method of the present invention.
[0118] Unless otherwise specified, the various raw materials of the present invention can be obtained from the market; or prepared according to conventional methods in the art. Unless otherwise defined or specified, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention.
[0119] The specific embodiments are as follows:
[0120] Chimeric antigen receptor and TCR inhibitor genes
[0121] The gene-editing-free universal CAR-T cell of the present invention and its preparation method and application include first preparing chimeric antigen receptor and TCR inhibitor genes, gene synthesis and sequence determination are completed by Shanghai Sangon Biotechnology Co., Ltd., and the synthesized insertion sequence is inserted into the framework of the pLenti-MCS-EF1-GFP Lentiviral Expression Vector plasmid vector, and the expression vector includes: EF1a promoter; position for insertion of foreign genes; WPRE element; SV40polyA sequence; regulatory elements such as promoter and enhancer; lentiviral packaging elements and other key elements. The lentiviral expression vector can be used as the most effective vector for expressing the target gene in almost all mammalian cells, including non-dividing cells and dividing cells. It can accommodate large foreign gene fragments, has high transfection efficiency, and can also achieve satisfactory transfection effects on T cells.
[0122] Example 1: Gene-editing-free universal CAR-T cells targeting MSLN and preparation method and application thereof
[0123] In the embodiment, the chimeric antigen receptor and TCR inhibitor gene synthesis and sequence determination targeting MSLN were completed by Shanghai Sangon Biotechnology Co., Ltd., wherein the sequence of the MSLN single-chain antibody is shown in SEQ ID NO. 2. The synthesized insertion sequence was inserted into the framework of the pLenti-MCS-EF1-GFP Lentiviral Expression Vector plasmid vector, and the competent cell DH5a was transformed, and the bacterial solution was plated on an agar plate containing ampicillin for culture; multiple clones were picked on the agar plate, inoculated into 5 ml of liquid LB medium (containing ampicillin), and cultured in a constant temperature shaker for 12-16 hours at 37°C and 250 rpm. Plasmids were extracted according to the instructions of the plasmid extraction kit (Cat. No.: DP103-03) purchased from Tiangen Biochemical Technology Co., Ltd., and each cloned plasmid was sent to Shanghai Biotech for Sanger sequencing to verify the accuracy of the inserted sequence; According to the sequencing data fed back by the sequencing company, the cloned bacterial solution with the correct sequence was selected for large-scale inoculation of shake flask culture; The vector plasmid was extracted using the MN company's endotoxin-free plasmid extraction kit, and the concentration and purity were measured using a spectrophotometer; The three packaging plasmids (pPACKH1-GAG, pPACKH1-REV and pVSV-G) were extracted using the MN company's endotoxin-free plasmid extraction kit, and the concentration and purity were measured using a spectrophotometer; The four-plasmid packaging system was used for lentiviral packaging. The four plasmids are the lentiviral expression plasmid containing the universal CAR structure, the lentiviral packaging plasmid lentiviral packaging plasmid pPACKH1-GAG, pPACKH1-REV and pVSV-G. The cells are 293T cells.
[0124] The specific implementation steps are as follows:
[0125] (1) Plate the cells within 24 hours before transfection: Generally, cells with a passage number of less than 3 are selected, and the cell density is adjusted according to the cell growth density and status. 293T cells with a growth density of 80% are plated;
[0126] (2) When the growth density reaches 60-90% and the cells are in good condition, virus packaging can be carried out;
[0127] (3) Use SBI lentiviral packaging plasmids pPACKH1-GAG, pPACKH1-REV and pVSV-G, as well as the two lentiviral plasmids constructed by the present invention, and prepare the lentiviral plasmids according to the SBI instructions.
[0128] (4) Select lipofectamine 2000 (stored at 4°C) as the transfection reagent, and add 2 μL / μg plasmid;
[0129] (5) Mix the plasmid mixture in (3) and the transfection reagent mixture in (4) in one tube, let it stand at room temperature for 20 min, then add it to the cells in the replacement medium and continue culturing;
[0130] (6) Collect the culture supernatant after 48 h and 72 h, respectively, and filter through a 0.45 μm filter membrane;
[0131] (7) The collected virus fluid was concentrated using the PEG8000 concentration method, the virus titer was determined, and it was stored at -80°C for future use.
[0132] Example 2: PBMC isolation, T cell activation, lentiviral infection and cell sorting
[0133] 1. PBMC Isolation
[0134] 1) Collect about 6 mL of fresh human peripheral blood using a vacuum blood collection tube containing heparin;
[0135] 2) Dilution: Add an equal volume of PBS at room temperature and mix gently by pipetting;
[0136] 3) Sample addition: Take a 50mL centrifuge tube, draw 6mL of Ficoll (lymphocyte separation fluid) into the centrifuge tube (the volume ratio of Ficoll to blood before dilution is 1:1), tilt the centrifuge tube at 45°, and slowly add the diluted blood onto the Ficoll along the tube wall at about 1cm above the Ficoll liquid surface;
[0137] 4) Centrifugation: 18-20℃, 2000rpm, 30min. After centrifugation, there are four layers from the bottom of the tube to the liquid surface, namely, red blood cell and granulocyte layer, stratified liquid layer, mononuclear cell layer, and plasma layer;
[0138] 5) Recovery: Insert the pipette directly into the cloud layer (or first suck out the upper plasma), gently suck out the cloud layer, and put it into a new centrifuge tube;
[0139] 6) Washing: Add PBS at least 3 times the volume of PBMC (peripheral blood mononuclear cells), 18-20℃, 2000rpm, 10min, twice;
[0140] 7) Cell counting: discard the supernatant, add 1mL lymphocyte culture medium, pipette and mix well to prepare PBMC cell suspension. Count using a blood cell counting plate: take a drop of PBMC suspension and a drop of 2% trypan blue dye solution, mix well and add to the blood cell counting plate, and count the total number of cells in 4 large squares under a microscope. Number of cells / mL = total number of cells in 4 large squares / 4×10 4 ×2 (dilution factor).
[0141] 2. T cell activation, lentiviral infection and cell sorting
[0142] Day-1: 24-well plate coating: Take a Corning 24-well plate, take 2 wells as an example, add 175μL of CD3 monoclonal antibody solution, 175μL of CD28 monoclonal antibody solution, and 175μL of CH-38 protein solution to each well. After adding, shake gently to mix, seal the well plate with sealing film, and place it in a 4℃ refrigerator overnight. Cell recovery: Take PBMC cells in liquid nitrogen and recover;
[0143] Day 0: Cleaning the coated plate: Take out the 24-well plate coated yesterday, discard the supernatant, wash twice with PBS, and add PBS for standby;
[0144] PBMC plating: Collect PBMC cells, count and adjust the final concentration to 5 × 10 6 cells / mL, add 400 μL of cell suspension to each well, that is, add 2×10 6 cells;
[0145] Virus infection: Infect with MOI = 5, prepare 1 mL of virus culture medium suspension, add to 24-well plate, centrifuge at 1000 g for 30 min, and adjust the centrifuge temperature to 32 °C;
[0146] Day1-Day2: Observe cell status;
[0147] Day 3: Transfer all cells in the 24-well plate to a 75 cm 2 In the culture flask, observe the cell status;
[0148] Day 9: Observe the cell status and cell number, resuspend by centrifugation, incubate CAR-T cells with biotin-MSLN antibody, and then use anti-biotin beads and magnetic separation columns to sort out biotin + Cells; Flow cytometry detection of MSLN CAR and CD3 positive rates before and after sorting ( Figure 3a~3e ), the sorted cells are the universal CAR-T cells targeting MSLN without gene editing, and subsequent experiments such as cell killing detection or cell freezing can be performed.
[0149] Example 3: Identification and detection of CAR-T cells obtained before and after sorting
[0150] 1. Detection of CAR structure positive expression rate
[0151] 1) The obtained NC group cells (not infected with virus) and sample group cells (infected with virus) were gently washed twice with PBS + 2% BSA at 1500 rpm / 6 min, and the waste liquid was discarded;
[0152] 2) Add 200 μL PBS to the NC tube and resuspend; add 100 μL PBS to the sample tube and resuspend, then add 100 μL primary antibody working solution (3 μg / mL) and mix well;
[0153] 3) Incubate at room temperature for 1 hour, 1500 rpm / 3 min, and discard the waste liquid;
[0154] 4) Add 200 μL PBS, gently mix and resuspend, 1500 rpm / 3 min, and discard the waste liquid;
[0155] 5) Add 200 μL PBS to the NC tube and resuspend; add 200 μL PBS to the sample tube and resuspend, then add 5 μL secondary antibody working solution and mix well;
[0156] 6) After incubation at room temperature in the dark for 1 hour, centrifuge at 1500 rpm / 3 min, discard the waste liquid, wash gently 3 times with PBS + 2% BSA, centrifuge at 1500 rpm, 3 min, and discard the waste liquid;
[0157] 7) Add 100 μL PBS, mix gently to resuspend and then test on the instrument.
[0158] like Figure 3d and 3e As shown, before sorting, universal CAR-T cells accounted for 65.79% of the total T cells, and after sorting, CAR-T cells accounted for 97.11% of the total T cells.
[0159] Example 4: qPCR detection of TCR inhibitor expression
[0160] Referring to Takara's TB Green® Premix Ex Taq™ II (Tli RNaseH Plus) instructions, the qPCR method was used to detect the overexpression level of TCR inhibitors. The DGKΑ detection primers used were synthesized by Sangon Biotech (Shanghai) Co., Ltd. The specific information is as follows:
[0161] TI-F: 5'- CAAGGACACCTACGACGCC -3', (SEQ ID NO. 10)
[0162] TI-R: 5'- TTCACTCTCAGGAACAAGGCA -3', (SEQ ID NO. 11)
[0163] hβ-Actin F: 5'-GGGAATCGTGCGTGACAT-3', (SEQ ID NO. 12)
[0164] hβ-Actin R: 5'-GAAGGTAGTTTCTGGATGCC-3'. (SEQ ID NO. 13)
[0165] The inhibitory effect is shown in the description of Example 7.
[0166] Example 5: RTCA real-time cell killing detection
[0167] 1) Take human ovarian cancer cell SKOV3 as an example (SKOV3 is a MSLN target positive cell, and MSLN target negative cell ES-2 is used as a control, see Figure 5a and Figure 5b ), after digestion, prepare a cell suspension, mix by pipetting, and then count the cells;
[0168] 2) Dilute the cell suspension to 5×10 4 cells / mL concentration, placed on ice for later use;
[0169] 3) Take out the RTCA test plate and add 50 μL of culture medium;
[0170] 4) Select the test procedure for this test in the RTCA detector program;
[0171] 5) Place the RTCA test board into the tester and observe whether the Messege item in the program is normal. If it is normal, start the experimental program;
[0172] 6) After program 1 is completed, remove the test plate and add 100 μL of tumor cell suspension to the corresponding wells. Mix each tube of cell suspension before adding;
[0173] 7) After adding the cell suspension, place the test plate in an incubator and let it stand for 30 minutes to allow the cells to settle naturally;
[0174] 8) After 30 minutes, place the test plate into the tester and run program 2;
[0175] 9) Observe the cell growth curve after 24 hours, and prepare to add effector T cells when the cells are in the logarithmic growth phase;
[0176] 10) Take out the effector T cells from the culture flask, centrifuge, wash, count, and prepare the effector group cell concentration according to different effector-target ratios;
[0177] 11) Pause the program, remove the test plate, add 50 μL of effector cells to the corresponding position, put it back into the detector, continue the program, and observe every day.
[0178] Figure 6a and Figure 6bTo detect the killing efficiency of MSLN-targeted universal CAR-T cells against SKOV3 tumor cells by RTCA;
[0179] Figure 6a and Figure 6b 1:1 means: effector cell: target cell = 1:1; "medium" means: no effector cells, only tumor target cells; uninfected T means: effector cells are uninfected T cells; common anti-MSLN CAR-T means: effector cells are T cells infected with common CAR structure virus; universal anti-MSLN CAR-T means: effector cells are T cells infected with universal CAR structure virus. Figure 6b As shown in the figure, the universal anti-MSLN CAR-T cells have obvious killing effects on tumor target cells, and the killing efficiency is not weaker than that of ordinary anti-MSLN CAR-T cells.
[0180] Example 6: ELISA detection of cytokine secretion
[0181] 1) Dilute 10× coating buffer with ddH2O and prepare 250× coating protein according to the proportion, for example, add 8 μL 250× coating protein to 2mL coating buffer;
[0182] 2) Add 100 μL / well of the coating solution prepared in 1) to the Corning 9018 Elisa high affinity 96-well plate, seal and place in a 4°C refrigerator overnight;
[0183] 3) Wash the coated 96-well plate three times with PBST (0.05% Tween 20);
[0184] 4) Prepare 5× blocking solution with ddH2O, add 200 μL / well, and block at room temperature for 1 hour;
[0185] 5) Add 1× blocking solution according to the requirements of the bottled standard and make 7 times of dilution. At the same time, dilute the sample (the supernatant after CAR-T cells kill tumor cells for 24 hours in the RTCA detection experiment) 5 times;
[0186] 6) Wash the blocked plate 5 times with PBST, add the standard and diluted sample solution, and incubate at room temperature for 2 hours or at 4°C overnight;
[0187] 7) Wash with PBST 4 times;
[0188] 8) Dilute 250× detection antibody with 1× blocking solution, add 100 μL / well, and incubate at room temperature for 1 hour;
[0189] 9) Wash 4 times with PBST, dilute 250×HRP with 1× blocking solution, add 100 μL / well, and incubate at room temperature for 30 min;
[0190] 10) Wash with PBST five times, add 100 μL of 1× TMB reagent to each well, and incubate at room temperature for 15 min;
[0191] 11) Add 50 μL / well of stop solution to stop color development;
[0192] 12) Detect OD value with an ELISA reader at 450nm.
[0193] Figure 7 This is the ELISA test of IFN factor after universal anti-MSLN CAR-T cells killed SKOV3 for 24 hours. The 1:1 in the figure means: effector cell: target cell = 1:1. After CAR-T cells and SKOV3 cells were co-cultured for 24 hours, there was obvious release of cytokine IFNγ.
[0194] Example 7: Inhibitory effect of universal anti-MSLN CAR-T cells on alloreactivity (GVHD effect)
[0195] 1) NCG mice were purchased and kept for one week before being divided into three groups: an uninfected T group, a common anti-MSLNCAR-T group, and a universal anti-MSLN CAR-T group.
[0196] 2) T cells were injected via tail vein at a dose of 5×10 7 The uninfected T group was injected with uninfected T cells, the common anti-MSLN CAR-T group was injected with sorted common anti-MSLN CAR-T cells, and the universal anti-MSLN CAR-T group was injected with sorted universal anti-MSLN CAR-T cells.
[0197] Figure 8 The results show that universal anti-MSLN CAR-T cells can inhibit allogeneic reactivity (GVHD effect) in a mouse model. Compared with mice injected with universal anti-MSLN CAR-T cells, mice injected with uninfected T cells and common anti-MSLN CAR-T cells showed obvious GVHD effects such as severe facial hair loss, redness and swelling of the eyes, and blindness.
[0198] The grading standard and grading of the GVHD effect are shown in Tables 1 and 2 below, respectively.
[0199] Table 1: Reference standards for clinical GVHD grading in mice
[0200]
[0201] Table 2 Grading of GVHD in mice
[0202]
[0203] In summary, the present invention provides a universal CAR-T cell that does not require gene editing, and a preparation method and application thereof. The universal CAR-T does not require gene editing, thus avoiding the off-target effects caused by gene editing and the cell damage caused by gene editing electroporation experiments. It can not only inhibit or even eliminate allogeneic reactivity (GVHD effect), but also greatly simplifies the universal CAR-T production process because it does not require cumbersome gene knockout.
[0204] It should be noted that the above embodiments can be freely combined as needed. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered as the protection scope of the present invention.
[0205] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately. In addition, it should be understood that after reading the above content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A universal CAR-T cell, wherein the universal CAR-T cell expresses a chimeric antigen receptor for a target cell surface antigen and a human TCR inhibitory factor, characterized in that: The human TCR inhibitor is derived from the human CD3ζ gene, and the nucleotide sequence of the human TCR inhibitor is shown in SEQ ID NO.
7.
2. The universal CAR-T cell according to claim 1, characterized in that: The chimeric antigen receptor and TCR inhibitor are connected by a cleavage protein.
3. The universal CAR-T cell according to claim 2, characterized in that: The shear protein is any one of T2A and P2A, and the nucleotide sequences are shown in SEQ ID NO.8 and SEQ ID NO.9 respectively.
4. The universal CAR-T cell according to claim 1 or 2, characterized in that: The universal CAR-T cells simultaneously express a chimeric antigen receptor against a target cell surface antigen and the human TCR inhibitor.
5. The universal CAR-T cell according to claim 1 or 2, characterized in that: The chimeric antigen receptor includes a signal peptide, an antigen binding domain, a transmembrane domain, a co-stimulatory domain and a signaling domain.
6. The universal CAR-T cell according to claim 1 or 2, characterized in that: The tumor surface antigen targeted by the chimeric antigen receptor on the surface of the CAR-T cell is at least one of CD19, CD20, BCMA, CD22, CD30, CD123, CD5, CD7, CD33, CEA, BRAF, MUC1, PSCA, GPC3, TERT, B7H3, PTEN, PD-1, PD-L1, NKG2D ligand, CD44v6, CD138, PSMA, NY-ESO, EGFR, HER2, Mesothelin, GD2, CD171 or VEGF.
7. The universal CAR-T cell according to claim 1 or 2, characterized in that: The vector used for preparing the universal CAR-T cells is DNA, RNA, plasmid, lentiviral vector, adenoviral vector, retroviral vector, transposon, other gene transfer systems or a combination thereof.
8. A carrier, characterized in that: Contains a nucleic acid encoding a chimeric antigen receptor and a human TCR inhibitor according to any one of claims 1 to 7.
9. A virus, characterized in that: Comprising the vector as claimed in claim 8.
10. A method for preparing a universal CAR-T cell according to any one of claims 1 to 7, characterized in that: It includes the following steps: Providing a T cell to be modified; and The T cells are transformed so that the T cells express the CAR, and the T cells express a chimeric antigen receptor and a human TCR inhibitor for the target cell surface antigen, and the nucleotide sequence of the human TCR inhibitor is as shown in SEQ ID NO.
7.
11. A pharmaceutical composition, characterized in that: include: (a) The universal CAR-T cell according to any one of claims 1 to 7; and (b) a pharmaceutically acceptable carrier, diluent or excipient.
12. A use of the universal CAR-T cell according to any one of claims 1 to 7, characterized in that: Used for preparing pharmaceutical compositions or preparations for treating cancer.
Citation Information
Patent Citations
T cell receptor-deficient T cell compositions
CN104395463A
Universal chimeric antigen receptor T cell preparation technology
CN109456943A
Targeted cytolysis of HIV-infected cells by Chimeric CD4 receptor bearing cells
CN1146136A
cell
WO2021205172A1
